

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Tedizolid Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions : Not applicable
on use

1.3 Details of the supplier of the safety data sheet

Company : MSD
117 16th Road
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person : EHSDATASTEWARD@msd.com
responsible for the SDS

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

H373 May cause damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

Tedizolid Phosphate

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Tedizolid Phosphate	856867-55-5	Repr. 2; H361d STOT RE 2; H373 (Bone marrow, Blood, Gastrointes- tinal tract) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	>= 50 - < 70

For explanation of abbreviations see section 16.

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|--|
| Risks | : | Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation. |
|-------|---|--|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- | | | |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
|------------------------------|---|--|

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
------------	---------	------------------	--------------------	-------

Tedizolid Injection Formulation

Version 4.0 Revision Date: 26.09.2025 SDS Number: 657055-00022 Date of last issue: 14.04.2025
 Date of first issue: 02.05.2016

		of exposure)		
Tedizolid Phosphate	856867-55-5	TWA	400 µg/m ³ (OEB 2)	Internal

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Tedizolid Phosphate	Fresh water	0,003 mg/l
	Marine water	0,003 mg/l

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Skin and body protection	:	Work uniform or laboratory coat.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	solid
Form	:	(lyophilised)
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	7,4 - 8,1
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han-

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Tedizolid Injection Formulation

Version 4.0	Revision Date: 26.09.2025	SDS Number: 657055-00022	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Tedizolid Phosphate:**

Acute oral toxicity	: LD50 (Rat): > 2.000 mg/kg LD50 (Mouse): > 2.000 mg/kg
Acute toxicity (other routes of administration)	: LD50 (Mouse): 256 - 274 mg/kg Application Route: Intravenous LD50 (Rat): 244 mg/kg Application Route: Intravenous LD50 (Dog): 200 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

Components:

Tedizolid Phosphate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: Chromosome aberration test in vitro
		Result: positive
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Result: negative
		Test Type: unscheduled DNA synthesis assay
		Species: Rat
		Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Tedizolid Phosphate:

Effects on fertility	:	Test Type: Fertility/early embryonic development
		Species: Rat, female
		Application Route: Oral
		Fertility: NOAEL: 15 mg/kg body weight
		Result: No effects on fertility
		Test Type: Fertility
		Species: Rat, male
		Application Route: Oral
		Fertility: NOAEL: 50 mg/kg body weight
		Result: No effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development
		Species: Mouse
		Application Route: Oral
		Developmental Toxicity: LOAEL: 25 mg/kg body weight
		Result: Reduced foetal weight, Skeletal malformations
		Test Type: Embryo-foetal development
		Species: Rat
		Application Route: Oral
		Developmental Toxicity: LOAEL: 15 mg/kg body weight
		Result: Reduced foetal weight, Skeletal malformations
		Test Type: Embryo-foetal development

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

	Species: Rat
	Application Route: Oral
	Developmental Toxicity: NOAEL: 2,5 mg/kg body weight
	Result: Reduced foetal weight, Skeletal malformations
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Tedizolid Phosphate:**

Target Organs	: Bone marrow, Blood, Gastrointestinal tract
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Tedizolid Phosphate:**

Species	: Rat, female
NOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 28 d
Target Organs	: Lymph nodes, thymus gland, Bone marrow

Species	: Rat, male
NOAEL	: 30 mg/kg
Application Route	: Oral
Exposure time	: 28 d
Target Organs	: Bone marrow, spleen, Lymph nodes, thymus gland

Species	: Rat, female
NOAEL	: 15 mg/kg
Application Route	: Intravenous
Exposure time	: 28 d
Target Organs	: Gastrointestinal tract

Species	: Rat, male
NOAEL	: 30 mg/kg
Application Route	: Intravenous
Exposure time	: 28 d
Target Organs	: Gastrointestinal tract

Species	: Rat
NOAEL	: 2 mg/kg
LOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 6 Months

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

Species	: Dog
NOAEL	: 400 mg/kg
Application Route	: Oral
Exposure time	: 28 d
Symptoms	: Vomiting

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Tedizolid Phosphate:

Inhalation	: Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness
Ingestion	: Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness

SECTION 12: Ecological information

12.1 Toxicity

Components:

Tedizolid Phosphate:

Toxicity to algae/aquatic plants	: EC50 (Anabaena flos-aquae): 0,313 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Anabaena flos-aquae): 0,0632 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 1
Toxicity to microorganisms	: EC50 : > 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC : 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	: NOEC: 0,03175 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic)	: NOEC: 0,6 mg/l Exposure time: 21 d

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

Acute toxicity)	Species: Daphnia magna (Water flea)
	Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 1

12.2 Persistence and degradability**Components:****Tedizolid Phosphate:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 2 % Exposure time: 28 d Method: OECD Test Guideline 301B
Stability in water	: Hydrolysis: 0 %(5 d)

12.3 Bioaccumulative potential**Components:****Tedizolid Phosphate:**

Partition coefficient: n-octanol/water	: log Pow: 1,3
--	----------------

12.4 Mobility in soil**Components:****Tedizolid Phosphate:**

Distribution among environmental compartments	: log Koc: 5,23 Method: OECD Test Guideline 106
---	--

12.5 Results of PBT and vPvB assessment**Product:**

Assessment	: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	--

12.6 Other adverse effects**Product:**

Endocrine disrupting potential	: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
--------------------------------	---

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Tedizolid Injection Formulation

Version 4.0	Revision Date: 26.09.2025	SDS Number: 657055-00022	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077
IMDG	:	UN 3077
IATA	:	UN 3077

14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid Phosphate)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid Phosphate)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid Phosphate)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid Phosphate)
IATA	:	Environmentally hazardous substance, solid, n.o.s. (Tedizolid Phosphate)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN Packing group	:	III
----------------------	---	-----

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards**ADN**

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

CA. DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H361d	: Suspected of damaging the unborn child.
H373	: May cause damage to organs through prolonged or repeated exposure.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL

Tedizolid Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.0	26.09.2025	657055-00022	Date of first issue: 02.05.2016

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 2	H361d
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN